Form 4: Prime Medicine Executive Meredith Goldwasser Acquires 90,500 Stock Options

Meredith Goldwasser, SVP of Strategy & Corporate Operations at Prime Medicine, Inc., reports the acquisition of 90,500 stock options exercisable at $2.42, vesting monthly from February 27, 2025.

Summary

• Meredith Goldwasser, SVP of Strategy & Corporate Operations at Prime Medicine, Inc., filed a Form 4 on March 3, 2025, reporting a transaction.
• On February 27, 2025, Goldwasser acquired 90,500 stock options with an exercise price of $2.42.
• These options vest in equal monthly installments over 48 months, starting February 27, 2025, contingent upon continued service.
• The options expire on February 27, 2035.
• Following the transaction, Goldwasser directly owns 90,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The granting of stock options is generally a positive sign, indicating confidence in the company's future. The vesting schedule promotes long-term alignment between the executive and shareholders.

Positives

• The acquisition of stock options by a key executive signals confidence in the company's future prospects.
• The vesting schedule incentivizes long-term commitment from the executive.

Future Outlook

The vesting schedule suggests an expectation of continued service and contribution from the executive over the next four years.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies.
• The vesting schedule of 4 years is typical for such grants, aligning executive incentives with long-term company performance.
• Comparing the size of the grant to similar companies like CRISPR Therapeutics or Editas Medicine would provide further context, but that information is not available in this document.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning executive interests with long-term value creation.
• Employees may see the grant as an indication of the company's commitment to its leadership team.

Key Dates